For Immediate Release

**Morepen secures Loratadine approval for export to China**

**Gurugram, India**, **1st April, 2025** - Morepen Laboratories Limited, a global leader in Active Pharmaceutical Ingredient (API) manufacturing, has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for its Loratadine (anti-allergy API). This marks a significant milestone in Morepen’s strategic **entry** into one of the world’s largest pharmaceutical markets.

Morepen commands an over **80% market share** in the US generics market for Loratadine, making it the undisputed leader in its category. The company has been exporting to the **US market for over 25 years**, its API **exports** alone are valued at **Rs.650 crores**. This approval further solidifies Morepen’s position as the dominant global manufacturer of Loratadine, a widely prescribed second-generation antihistamine and anti-allergy drug used to treat allergic symptoms such as hay fever and chronic urticaria. With this development, Morepen is poised to capture a significant share of the Chinese market while reinforcing its standing in the global pharmaceutical landscape.

**Strategic Expansion in China**

“The approval by China’s NMPA is a testament to Morepen’s unwavering commitment to quality, regulatory excellence, and global market expansion,” said **Kushal Suri, Director – Sales & Marketing, Morepen Laboratories.** “China represents a vast growth opportunity, and this milestone will allow us to meet the increasing demand for high-quality antihistamine and anti-allergy APIs while reinforcing our leadership in global healthcare.”



Morepen is the **number one APIs exporter out of India** for six leading products, including **Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine**. The company exports to **82 countries** and has a **manufacturing capacity of 144 metric tons API annually**.

With world-class manufacturing facilities at **Masulkhana and Baddi, both USFDA-approved**, Morepen continues to expand its footprint across regulated and emerging markets, including the **US, Europe, Japan, China, and Russia**. The company holds **167 patents; 27 USDMFs; 12 CEP filings; 10 China IDLs; 278 other DMFs, and 44 new products in its portfolio**. Loratadine also holds approved USDMF, CEP, and IDL China registrations, along with 23 additional other DMFs and three granted patents.

**A Legacy of Excellence in Loratadine Manufacturing**

Morepen Laboratories has been at the forefront of Loratadine production since **1993**, when it became the first Indian company to manufacture the molecule. Over the years, the company has built a reputation for **quality, innovation, and regulatory compliance**, securing approvals from major global authorities, including the **USFDA**.

**About Morepen Laboratories Ltd.**

Morepen Laboratories, established in 1984, is a leading player in the pharmaceutical and healthcare industry. With a strong presence in APIs, medical devices, and finished formulations, Morepen has consistently demonstrated innovation and market leadership. The company is a global leader in exporting 6 key API products, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine.

In the medical devices segment, Morepen has made remarkable strides in Point of Care (POC) diagnostics, having installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, driving expansion into tier-2 and tier-3 cities.

For more details, visit [www.morepen.com](http://www.morepen.com).

Media Contact:

Morepen Laboratories Ltd.

Corporate Office: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar – III, Sector 20, Gurugram, Haryana – 122016  
Email: [corporate@morepen.com](mailto:corporate@morepen.com)

Nitika Saini, Manager – Corporate Communication | +91 9818533004

Forward-Looking Statements:

This press release contains forward-looking statements based on current expectations and assumptions regarding anticipated developments and other factors affecting the company. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.